You are here

Cross-matching of MSCs and Immune Responses

The mesenchymal stem cell (MSC) regenerative medicine dogma has been one of absolute immune privilege. This notion, taken together with the commercial advantages of allogeneic cell lines, has led to a majority of preclinical and clinical studies utilizing non–cross‐matched MSCs despite a lack of scientific evidence for allogeneic superiority. Now, research presented in a new STEM CELLS Translational Medicine article from the lab of Ashlee E. Watts (Texas A&M University, Texas, USA) provides evidence that the use of non–cross‐matched allogeneic MSCs may be the Achilles' heel for reliable and predictable MSC efficacy. Rowland et al. hope that this article will accelerate a paradigm shift away from non–cross‐matched allogeneic MSC clinical trials and pave the way to regulatory approval for disorders that currently do not have adequate medical therapies.